Dexmedetomidine as an Adjuvant in Peripheral Nerve Block
Zheping Chen,Zhenzhen Liu,Chang Feng,Yanwu Jin,Xin Zhao
DOI: https://doi.org/10.2147/dddt.s405294
2023-05-17
Abstract:Zheping Chen, Zhenzhen Liu, Chang Feng, Yanwu Jin, Xin Zhao Department of Anesthesiology, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250012, People's Republic of China Correspondence: Yanwu Jin; Xin Zhao, Email ; Peripheral nerve block technology is important to balanced anesthesia technology. It can effectively reduce opioid usage. It is the key to enhance clinical rehabilitation as an important part of the multimodal analgesia scheme. The emergence of ultrasound technology has accelerated peripheral nerve block technology development. It can directly observe the nerve shape, surrounding tissue, and diffusion path of drugs. It can also reduce the dosage of local anesthetics by improving positioning accuracy while enhancing the block's efficacy. Dexmedetomidine is a highly selective drug α 2 -adrenergic receptor agonist. Dexmedetomidine has the characteristics of sedation, analgesia, anti-anxiety, inhibition of sympathetic activity, mild respiratory inhibition, and stable hemodynamics. Numerous studies have revealed that dexmedetomidine in peripheral nerve blocks can shorten the onset time of anesthesia and prolong the time of sensory and motor nerve blocks. Although dexmedetomidine was approved by the European Drug Administration for sedation and analgesia in 2017, it has not yet been approved by the US Food and Drug Administration (FDA). It is used as a non-label drug as an adjuvant. Therefore, the risk-benefit ratio must be evaluated when using these drugs as adjuvants. This review explains the pharmacology and mechanism of dexmedetomidine, the effect of dexmedetomidine on various peripheral nerve block as an adjuvant, and compare it with other types of adjuvants. We summarized and reviewed the application progress of dexmedetomidine as an adjuvant in nerve block and look forward to its future research direction. Keywords: dexmedetomidine, alpha‐2 agonists, adjuvant, peripheral nerve block, anesthesia, analgesic In 1885, William Stewart Halsted discovered that injecting cocaine into specific parts of the nerve (around the plexus and nerve trunk) can block the sensory conduction of human nerves through self-experiment. Therefore, he invented nerve block anesthesia and pioneered regional nerve block. 1 Numerous traditional regional anesthesia technologies have realized visualization with the help of ultrasound with the continuous development of ultrasound technology. Peripheral nerve blocks (PNB) technology is increasingly significant in perioperative analgesia and clinical anesthesia. PNB or PNB combined with general anesthesia (GA) can reduce persistent incision and visceral pain, reduce opioid usage, shorten hospital stay, and reduce the recurrence rate of some cancers compared to GA, consistent with the concept of enhanced recovery after surgery (ERAS) advocated by modern medicine. 2,3 PNB is now well-established as an integral part of a balanced anesthetic technique and constitutes a vital component of a multimodal analgesic regimen that enhances ERAS. Figure 1 Multiple sites of action of dexmedetomidine (peripherally and centrally). PNB has become the cornerstone of perioperative pain management in modern surgical practice. The finite duration of single injection techniques is one of the greatest limitations of PNB in acute pain management. Continuous catheter techniques are widely employed to prolong regional analgesia; however, they have several drawbacks, such as the difficulty of catheter removal and the increased risk of infection. 4,5 Single-injection PNB is an attractive option because it is technically easier and can be performed quickly. Therefore, there is a growing demand to identify a reliable solution for prolonging analgesia duration from PNB. Different agents have been combined with local anesthetics (LA) over the years to prolong the duration of action, with varying degrees of success. Analgesic adjuvants include opioids, epinephrine, sodium bicarbonate, magnesium sulfate, dexamethasone, ketorolac, ketamine, neostigmine, midazolam, cortisol, and α2-adrenergic receptor (α 2 -AR) agonists. 6–8 The existing randomized controlled studies (RCTs) and meta-analysis exhibit that adding LA adjuvant to peripheral nerve block helps to prolong the analgesic time, 9 can significantly improve the quality of PNB, 7,8 and has a synergistic analgesic effect with LA. Most adjuvants are safe; neurotoxicity and tissue damage are rare. Although these drugs synergize when used as an adjuvant with LA, several studies have reported systemic adverse reactions, such as itching, nausea, and vomiting caused by opioids, including fentanyl and buprenorphine. 10,11 Dexamethasone excessively prolonged the analgesic time, resulting in the slow recovery of postoperative -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal